Instil Bio, Inc. (TIL)
5.795
-0.28
(-4.69%)
USD |
NASDAQ |
Nov 16, 15:37
Instil Bio Debt to Equity Ratio : 0.8141 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.8141 |
| March 31, 2026 | 0.7695 |
| December 31, 2025 | 0.7481 |
| September 30, 2025 | 0.7052 |
| June 30, 2025 | 0.6447 |
| March 31, 2025 | 0.5981 |
| December 31, 2024 | 0.5128 |
| September 30, 2024 | 0.484 |
| June 30, 2024 | 0.439 |
| March 31, 2024 | 0.4169 |
| December 31, 2023 | 0.3811 |
| September 30, 2023 | 0.3686 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.2937 |
| March 31, 2023 | 0.2679 |
| December 31, 2022 | 0.2197 |
| September 30, 2022 | 0.1726 |
| June 30, 2022 | 0.1247 |
| March 31, 2022 | 0.0166 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0518 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1901 |
| Savara, Inc. | 0.2815 |
| Arrowhead Pharmaceuticals, Inc. | 27.84 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 197.71M |
| Total Liabilities (Quarterly) | 90.33M |
| Shareholders Equity (Quarterly) | 107.38M |
| Current Ratio | 21.67 |
| Net Debt Paydown Yield | -0.29% |